Aligos Therapeutics, Inc.
General ticker "ALGS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $80.5M (TTM average)
Aligos Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -24.0%.
Estimated limits based on current volatility of 3.7%: low 5.10$, high 5.50$
Factors to consider:
- Total employees count: 82 (+17.1%) as of 2025
- Top business risk factors: Product development failure, Regulatory and compliance, Commercialization challenges, Capital raising, Supply chain disruptions
- Current price 11.1% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.47$, 18.94$]
- 2026-12-31 to 2027-12-31 estimated range: [3.77$, 13.83$]
Financial Metrics affecting the ALGS estimates:
- Negative: with PPE of -1.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: negative Industry operating income (median)
- Negative: 58.56 < Shareholder equity ratio, % of 60.48 <= 69.38
- Positive: -28.70 < Return on assets ratio (scaled to [-100,100]) of -21.46
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ALGS quotes
Long-term ALGS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $15.53MM | $3.94MM | $2.19MM |
| Operating Expenses | $103.66MM | $93.10MM | $90.17MM |
| Operating Income | $-88.13MM | $-89.15MM | $-87.98MM |
| Non-Operating Income | $1.24MM | $-41.73MM | $64.11MM |
| R&D Expense | $73.04MM | $70.27MM | $69.45MM |
| Income(Loss) | $-86.88MM | $-130.88MM | $-23.88MM |
| Taxes | $0.80MM | $0.33MM | $0.31MM |
| Net Income(Loss)* | $-87.68MM | $-131.21MM | $-24.19MM |
| Stockholders Equity | $92.08MM | $-28.97MM | $53.55MM |
| Assets | $151.53MM | $70.09MM | $88.53MM |
| Operating Cash Flow | $-79.00MM | $-80.74MM | $-82.50MM |
| Capital expenditure | $0.02MM | $0.13MM | $0.44MM |
| Investing Cash Flow | $44.98MM | $-18.28MM | $-37.83MM |
| Financing Cash Flow | $88.33MM | $0.35MM | $101.64MM |
| Earnings Per Share** | $-3.52 | $-20.94 | $-2.45 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.